Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2022 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
January 10, 2022 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates

- Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated enhanced...
January 06, 2022 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
January 04, 2022 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
November 03, 2021 07:05 ET | Source: Solid Biosciences Inc.

Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results

- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 - - Continued progress with SGT-003; Solid’s next-generation Duchenne gene...
November 02, 2021 07:30 ET | Source: Solid Biosciences Inc.; The Pathway Development Consortium; REGENXBIO Inc.

Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development

- Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development - - Pathway Development...
October 21, 2021 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
September 29, 2021 07:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post...
September 23, 2021 06:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital...
September 20, 2021 16:05 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021...